SIX:BSLN
Basilea Pharmaceutica AG · SIX · Healthcare · CHF · FY for 2025
Figures on this page computed 2026-11-08 12:44 UTC
Last close
n/aCHF
Market data
21.6xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CHF
- computed
- Computed from the filing for 2025
24.2%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CHF
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
17.3%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CHF
- Computed from the filing for 2025
- Computed from the filing for 2025
25.5%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CHF
- Computed from the filing for 2025
- Computed from the filing for 2025
0.70Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CHF
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CHF
- computed
Growth is the furthest below its sector's middle: 0.43 against 0.50 on the market's range.
- Growth12.7%43 of 100, below its sector
- Returns on capital24.2%92 of 100, above its sector
- Margins83.1%88 of 100, above its sector
- Price21.6x31 of 100, below its sector
- Safety0.7062 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
All from 100
lens 2 of 9Sales
352Shares in issue
126- Profit, where the first year is 100: n/aNot enough filed years carry this line for it to be drawn. No line is drawn flat in its place.
Sales is at 352, Shares in issue is at 126, against 100 in 2016.
Sales is at 352, Shares in issue is at 126, against 100 in 2016.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2025
Sales, where the first year is 100352
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CHF
Profit, where the first year is 100n/a
Not held.
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CHF
Shares in issue, where the first year is 100127
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CHF